Olmesartan medoxomil exporter, documenting the FDA sprue-like enteropathy safety signal unique among ARBs
In July 2013 the FDA approved a label change for olmesartan medoxomil adding sprue-like enteropathy, a villous-atrophy intestinal disorder causing severe diarrhea and weight loss, a signal the agency's review did not detect with other ARB molecules. M Care Exports supplies olmesartan medoxomil tablets across 35 catalogue lines from WHO-GMP certified Indian manufacturers, with that labelling history documented in every export dossier for regulatory affairs and pharmacovigilance teams.
Olmesartan medoxomil exporter and bulk supplier from India.
M Care sources olmesartan medoxomil tablets across 35 product lines in its catalogue, drawn from WHO-GMP certified Indian manufacturers, to match tender and distributor specifications on strength and pack format. Export documentation is assembled per shipment: Certificate of Analysis, Certificate of Pharmaceutical Product or Free Sale Certificate, manufacturer's WHO-GMP certificate, and CTD/eCTD-format dossier modules for markets requiring registration filings. Cold-chain is not required; olmesartan medoxomil tablets are stored and shipped at controlled room temperature per manufacturer stability data, which M Care requests and forwards alongside each consignment. Given the molecule's enteropathy labelling history, M Care includes current manufacturer safety labelling text and any pharmacovigilance correspondence in the documentation pack so the importer's regulatory team can align local product information before the consignment clears customs.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Angiotensin II receptor blocker (ARB), AT1 receptor antagonist, benzimidazole derivative, sourced and documented for export.
Olmesartan medoxomil carries an FDA label warning, unique among ARBs, for sprue-like enteropathy, a villous-atrophy intestinal disorder that can present years after treatment starts: this is the single most important thing a buyer must know before ordering. Regulatory affairs and pharmacovigilance teams importing this molecule should have current safety labelling text on file and confirm the receiving market's own label reflects the 2013 US labelling action, since national labels outside the US vary in how, or whether, they carry this warning. Beyond that signal, olmesartan medoxomil is a benzimidazole-derivative angiotensin II type 1 (AT1) receptor antagonist, rapidly hydrolysed to its active moiety olmesartan on absorption. It is indicated for hypertension, used alone or with other antihypertensive classes including thiazide diuretics and calcium channel blockers, and is available as film-coated tablets in three strengths.
Active ingredient
Olmesartan medoxomil (prodrug, hydrolysed to olmesartan). Angiotensin II receptor blocker (ARB), AT1 receptor antagonist, benzimidazole derivative.
Forms and strengths
10 mg; 20 mg; 40 mg.
Indications
Olmesartan medoxomil is an orally administered prodrug that is rapidly hydrolysed during absorption to olmesartan, an angiotensin II type 1 (AT1) receptor antagonist used for the management of hypertension. It carries a distinct FDA labelling history: a 2013 label change added sprue-like enteropathy, a villous-atrophy intestinal disorder, as an adverse effect not detected with other ARBs in the same review.
Administration
Oral. Film-coated tablet.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers ordering olmesartan medoxomil through M Care are typically hospital procurement desks, tender authorities and licensed pharmaceutical importers in the UK and EU, the Gulf and wider GCC, African national and private distribution networks, Latin America and Southeast Asia, and CIS markets, sourcing an established ARB for hypertension formularies. Regulatory affairs teams within these organisations are the primary technical contact, since registration filings and safety labelling review sit with them rather than with commercial buyers. Demand tends to come from importers replacing or diversifying an existing ARB supply line, or filling a formulary gap for a molecule with documented comparative blood-pressure efficacy data against other agents in its class. India is M Care's sourcing base only and is not a served market for this molecule.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on olmesartan medoxomil.
A dispensing or clinical pharmacist reviewing olmesartan medoxomil checks for unexplained chronic diarrhea and unintended weight loss in any patient on the drug, since sprue-like enteropathy can present months to years after initiation and is easily mistaken for celiac disease on initial workup. The distinguishing point for chart review: villous atrophy on duodenal biopsy with negative celiac serology, and clinical improvement on withdrawal of olmesartan rather than a gluten-free diet, is the pattern reported in the case series underlying the 2013 label change. Beyond that signal, standard ARB checks apply: renal function and serum potassium at initiation and after dose titration, particularly in patients on concurrent potassium-sparing diuretics or NSAIDs; blood pressure response before dose escalation from 20 mg to 40 mg; and confirmation the patient is not pregnant or planning pregnancy, given the class contraindication. Hepatic impairment does not require the dose caution associated with some other ARBs; olmesartan's clearance profile is not the basis for this page's dosing caution and should be checked against current product labelling rather than assumed from class norms.
The documentation pack a regulator actually asks for.
Each olmesartan medoxomil consignment is supplied with a Certificate of Analysis confirming assay, dissolution, related substances and impurity profile against pharmacopoeial specification, plus a Free Sale Certificate or Certificate of Pharmaceutical Product from the country of manufacture. Manufacturer WHO-GMP certificates are provided for the specific facility supplying the batch, since M Care is a merchant-exporter and does not hold manufacturing certification itself. Stability data supporting the shelf life and storage claims on the pack is available from the sourcing manufacturer on request, relevant here given no cold-chain requirement applies to this molecule. For buyers requiring a registration filing, dossier modules are supplied in CTD or eCTD format covering Module 3 (quality) as a baseline, with Module 2 summaries where the manufacturer provides them; buyers should confirm module scope against their specific registration requirement before order placement. Given the molecule's labelling history, M Care includes the manufacturer's current core safety information and any available pharmacovigilance correspondence referencing the sprue-like enteropathy signal, so the importer's regulatory affairs team can verify destination-market product information is current before the consignment is offered for sale. No controlled-drug import permit applies to olmesartan medoxomil.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
What a buyer should know before this line enters a formulary.
We publish the awkward facts alongside the useful ones. A supplier who omits them is not saving you work, only deferring it.
Prescription-only medicine in all served markets
FDA label change (July 2013) adds sprue-like enteropathy as an adverse effect; signal not detected with other ARB molecules in the same review
Contraindicated in pregnancy: renin-angiotensin-system-acting drugs can cause fetal harm in second and third trimester exposure
Angioedema has been reported post-marketing with olmesartan medoxomil; use caution in patients with a prior history of angioedema, consistent with other ARB-class labelling
M Care Exports is a merchant-exporter; it does not itself hold WHO-GMP or WHO-PQ certification; supply is sourced from WHO-GMP certified Indian manufacturers
M Care's own credentials are ISO 9001:2015 and CDSCO license; India is a sourcing base, not a served market
Adjacent lines procurement desks order alongside olmesartan medoxomil.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for olmesartan medoxomil.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Olmesartan medoxomil supply, the specific questions.
Does M Care hold WHO-GMP or WHO-PQ certification directly?
No. M Care Exports is a merchant-exporter, not a manufacturer, and does not itself hold WHO-GMP or WHO-PQ status. Olmesartan medoxomil lines in the M Care catalogue are sourced from Indian manufacturers that hold WHO-GMP certification for their facilities, and those certificates are supplied with each consignment's documentation pack. M Care's own credentials are ISO 9001:2015 and a CDSCO license.
What is the sprue-like enteropathy warning on olmesartan, and does it affect the whole ARB class?
In July 2013 the FDA approved a label change adding sprue-like enteropathy, a condition of severe chronic diarrhea, weight loss and intestinal villous atrophy that can present months to years after starting the drug, based on a case review. The FDA noted this signal had not been detected with other ARB molecules in the same review, so it is treated as specific to olmesartan rather than a class effect.
Can olmesartan medoxomil be used in pregnancy?
No. Like other drugs acting on the renin-angiotensin system, olmesartan medoxomil carries a contraindication in pregnancy due to the risk of fetal harm, including oligohydramnios, renal impairment and skeletal deformation when used in the second and third trimesters. This is a standard ARB-class restriction, not specific to olmesartan, and importers should confirm it is reflected in destination-market labelling.
What strengths and pack formats does M Care supply?
M Care's catalogue holds 35 distinct olmesartan medoxomil product lines from Indian manufacturers, covering the marketed tablet strengths of 10 mg, 20 mg and 40 mg. Specific brand names, pack sizes and quantities are confirmed against the buyer's tender or purchase specification at enquiry stage rather than published generically, since manufacturer sourcing varies by shipment.
What documentation does M Care provide with an olmesartan shipment?
Each consignment is accompanied by a Certificate of Analysis, a Certificate of Pharmaceutical Product or Free Sale Certificate, the manufacturer's WHO-GMP certificate, and CTD/eCTD-format dossier modules where the destination market requires a registration filing. Stability data is provided on request from the sourcing manufacturer.
How should a pharmacovigilance team monitor patients on olmesartan after import?
Prescribers and dispensing pharmacists should be alerted to investigate unexplained chronic diarrhea and unintended weight loss in patients on olmesartan, particularly when celiac serology is negative, and to consider discontinuation if no other cause is found. Clinical improvement after stopping olmesartan has been consistently reported, which supports drug withdrawal as the primary management step rather than continued diagnostic workup for celiac disease.
We already stock telmisartan and losartan. What would move us to olmesartan?
On blood-pressure efficacy at equivalent doses, very little. The distinguishing fact runs the other way: olmesartan is the ARB carrying the sprue-like enteropathy labelling, so a formulary adding it takes on a pharmacovigilance line the other two do not have. Buyers usually order olmesartan because a prescriber base or a tender specification already names it, not because it outperforms the alternatives.
Does the enteropathy signal apply to olmesartan combination products?
Yes. The labelling attaches to the olmesartan moiety, so fixed-dose combination lines pairing it with amlodipine or hydrochlorothiazide carry the same signal. Combination-branded lines in our catalogue are not exempt, and a receiving market's label for the combination should reflect the warning in the same terms as the single-agent label.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-08-22.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.